Journal
LANCET
Volume 370, Issue 9600, Pages 1698-1705Publisher
LANCET LTD
DOI: 10.1016/S0140-6736(07)61605-5
Keywords
-
Categories
Funding
- FIC NIH HHS [K01-TW05708, K01-TW06670] Funding Source: Medline
- NIAID NIH HHS [K23-AI01411] Funding Source: Medline
Ask authors/readers for more resources
Background Intraparturn and neonatal single-dose nevirapine are essential components of perinatal HIV prevention in resource-constrained settings, but can induce resistance to other non-nucleoside reverse transcriptase inhibitor drugs. We aimed to investigate whether this complication would be reduced with a single peripartum intervention of tenofovir and erntricitabine. Methods We randomly assigned 400 HIV-infected pregnant women who sought care at two public-sector primary health facilities in Lusaka, Zambia. One was excluded, 200 were assigned to receive a single oral dose of 300 mg tenofovir disoproxil fumarate with 200 mg erntricitabine under direct observation, and 199 to receive no study drug. Short-course zidovudine and intrapartum nevirapine were offered to all HIV-infected women, according to the local standard of care. Women who met national criteria for antiretroviral therapy were referred for care and not enrolled. Our pnmary study outcome was resistance to non-nucleoside reverse transcriptase inhibitors at 6 weeks after delivery. We used standard population sequencing to determine HIV genotypes. Analysis was per protocol. This study is registered with ClinicalTrials.gov, number NCT00204308. Findings Of the 200 women who were randomly assigned to the intervention, 14 were lost to follow-up or withdrew from the study, two did not take study drug according to protocol, and one specimen was lost; 23 of 199 controls were lost to follow-up or withdrew from the study, and three specimens were lost. Women given the intervention were 53% less likely than controls to have a mutation that conferred resistance to non-nudeoside reverse transcriptase inhibitors at 6 weeks after delivery (20/173 [12%] vs 41/166 [25%;; risk ratio [RR] 0.47, 95% CI 0.29-0.76). We noted postpartum anaernia, the most common serious adverse event in mothers, in four women in each group. 20 of 198 (10%) infants in the intervention group and 23 of 199 (12%) controls had a serious adverse event, mostly due to septicaernia (n=22) or pneumonia (n=8); these events did not differ between groups, and none were judged to be caused by the study intervention. Interpretation A single dose of tenofovir and erntricitabine at delivery reduced resistance to non-nucleoside reverse transcriptase inhibitors at 6 weeks after delivery by half, therefore this treatment should be considered as an adjuvant to intrapartum nevirapine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available